Hypercortisolism

In patients with hypercortisolism and difficult-to-control type 2 diabetes, mifepristone lowered HbA1c at 24 weeks compared with placebo, researchers reported at World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.

Adults diagnosed with endogenous Cushing’s syndrome have a higher risk for developing cancer compared with controls without the condition, according to data published in the European Journal of Endocrinology.

Teva Pharmaceuticals launched the first generic GLP-1 receptor agonist, liraglutide 1.8 mg, for patients aged 10 years or older with type 2 diabetes.

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.

Presentations on the SURMOUNT-OSA, FLOW, INHALE-3 and TIGHT trials are among the many highlights at the American Diabetes Association’s 84th Scientific Sessions.

NEW ORLEANS —A small group of adults with mild autonomous cortisol secretion had an increase in spine trabecular bone score following adrenalectomy, according to a speaker at the AACE annual meeting.

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label portion of the GRACE phase 3 trial.

Hypercortisolism is prevalent among nearly one-quarter of people with difficult-to-control type 2 diabetes enrolled in a prospective phase 4 study, according to an industry press release.

More than 80% of adults with Cushing’s disease receiving osilodrostat had normalized mean urinary free cortisol levels at 72 weeks of treatment, according to findings from the LINC 3 study extension.

SAN DIEGO — Osilodrostat is associated with improvements in physical manifestations of hypercortisolism and reductions in mean body weight and BMI in adults with Cushing’s syndrome, according to a speaker.